Vericel has delivered a solid 31.4% share price gain over the past year, which naturally puts a spotlight on whether that move lines up with the cash the business is expected to generate. With the stock last closing at US$39.71, the key issue for you is whether that market value can be reconciled with what its cash flows imply through a Discounted Cash Flow (DCF) lens.
-
The 31.4% one year return has rewarded existing holders, so any fresh money coming in now needs a clear view on what the underlying cash generation can support.
-
Vericel's ability to turn its current product portfolio and operating model into steady, recurring cash flows may support different expectations for future reinvestment needs and potential surplus cash for shareholders.
-
What if you looked at Vericel through its earnings instead? See what Vericel's 84.0x P/E says about the price .
The stock's next move may depend on whether Vericel's recent share price is fully explained by the cash flows implied in its intrinsic value estimate.
If you are weighing Vericel through the lens of its cash flows, it can help to compare that story with other businesses that screen as 32 high quality undervalued stocks .
Does Vericel Look Pricey on Cash Flow?
The Discounted Cash Flow (DCF) model here is built around what Vericel can generate in free cash over time rather than short term earnings swings. On the latest twelve month numbers, the business produced roughly $26.4 million of free cash flow, so this is not a zero cash story. The projection path used in the model assumes growing cash flows over the coming decade before fading to a steadier pattern.
When those future cash streams are discounted back into today's dollars, the DCF estimate comes out substantially below the current share price of US$39.71. That indicates the market is placing a richer value on Vericel than the model implies based purely on these cash flow assumptions. As a result, any interest at today's level leans more on confidence in the franchise and pipeline than on this particular cash flow math alone. Find out what Vericel could be worth using our Discounted Cash Flow (DCF) estimate .
The Vericel Narrative: What Would Justify Today's Price?
Vericel's Simply Wall St Narratives pick up where the DCF puzzle leaves off, explaining which paths for revenue, margins and earnings would need to occur for today's share price to appear high, fair or low. Each narrative appears on the Community page and treats Vericel's fair value as a thesis you can track over time, allowing you to see how well the underlying assumptions hold up instead of only getting a single snapshot.
One of the top community narratives on Vericel: 28% undervalued
"This narrative explores a more pessimistic perspective on Vericel compared to the consensus, based on a Fair Value that aligns with the bearish cohort..."
Discover why this Narrative puts Vericel at 28% undervalued .
One more Vericel factor that could sway your view
The cash flow story for Vericel only goes so far without knowing who is steering the ship, how aligned they are with shareholders and what their pay packages really encourage. See who runs Vericel and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include VCEL .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
